The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | Bortezomib-based triplet regimens in MM patients undergoing transplantation
Surbhi Sidana, MD, Stanford University, Stanford, CA, discusses the findings of a large CIBMTR registry study, comparing VRD (bortezomib, lenalidomide and dexamethasone) to VCD (bortezomib, cyclophosphamide and dexamethasone) induction therapy in multiple myeloma patients undergoing autologous stem cell transplant (ASCT). 1135 transplant patients were identified who had shown at least a partial response to VCD or VRD induction therapy. Pre-transplant responses were comparable between groups, and no difference in outcome was seen based on induction therapy received once prognostic factors were adjusted for. The study also showed that maintenance treatment was associated with superior outcomes. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
